Seaport Research lowered the firm’s price target on Ascend Wellness to $5 from $6 and keeps a Buy rating on the shares. After four quarters of beating revenue and AEBITDA estimates, the company reported Q2 results that were below the firm’s expectations, the analyst tells investors. Despite this, Seaport continues to believe the company’s strong execution, retail prowess, and marketing & acquisition upside make it the “most underappreciated” story in the cannabis sector.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AAWH: